Today announced economic results for the quarter and yr ended December 31.

GAAP R&D expenditures for 2013 were $317.1 million, compared to $222.7 million in 2012. GAAP SG&A expenditures for 2013 were $489.7 million, compared to $384.7 million for the last year. Fourth One fourth Non-GAAP Financial Results The Company reported non-GAAP net income of $177.7 million, or $0.87 per talk about in Q4 2013, in comparison to non-GAAP net income of $122.3 million, or $0.60 per share, in Q4 2012. Alexion's non-GAAP operating expenses for Q4 2013 were $201.7 million, in comparison to $163.2 million for Q4 2012. Non-GAAP R&D expenditures for Q4 2013 had been $79.8 million, compared to $59.9 million for Q4 2012. Non-GAAP SG&A expenses for Q4 2013 had been $121.8 million, in comparison to $103.3 million for Q4 2012.Study formulas were prepared and coded with the use of four shades by Mead Johnson Diet, which kept the codes. Newborn infants requiring supplemental feeding before randomization received banked breast milk or Nutramigen. The codes, that have been broken, as specified by the protocol, when the youngest child in the study completed the intervention, revealed that 113 infants had been randomly designated to the casein hydrolysate group and 117 to the control group. There have been no differences in the distribution of HLA genotypes or of affected family between the two groups . Breast-feeding was practiced at the discretion of the participating moms, and maternal diet plans were unmodified. Breast-feeding was encouraged and exceeded national averages in both study groups.